Pharmacodynamic effect of a new γ‐secretase modulator, RG6289, on CSF amyloid‐β peptides in a random...
Pharmacodynamic effect of a new γ‐secretase modulator, RG6289, on CSF amyloid‐β peptides in a randomized Phase I study
About this item
Full title
Author / Creator
Publisher
Hoboken: John Wiley and Sons Inc
Journal title
Language
English
Formats
Publication information
Publisher
Hoboken: John Wiley and Sons Inc
Subjects
More information
Scope and Contents
Contents
Background
γ‐Secretase modulators (GSMs) represent a promising therapy for Alzheimer’s disease (AD). GSMs selectively reduce amyloidogenic long Aβ peptides (e.g.: Aβ42) while simultaneously increasing shorter, non‐amyloidogenic, Aβ species (Aβ38 and Aβ37). Here we report the results of pharmacodynamic (PD) effects of RG6289, a novel, potent and...
Alternative Titles
Full title
Pharmacodynamic effect of a new γ‐secretase modulator, RG6289, on CSF amyloid‐β peptides in a randomized Phase I study
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11713813
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11713813
Other Identifiers
ISSN
1552-5260
E-ISSN
1552-5279
DOI
10.1002/alz.095213
